Eupraxia Pharmaceuticals (EPRX) Non-Current Debt (2022 - 2024)

Eupraxia Pharmaceuticals (EPRX) has 3 years of Non-Current Debt data on file, last reported at $21209.0 in Q2 2024.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $21209.0 in Q2 2024; TTM through Jun 2024 was $21209.0, a N/A change from a year earlier, with the FY2023 full-year figure at $62709.0, changed 0.0% from the prior year.
• Non-Current Debt for Q2 2024 stood at $21209.0, down from $42112.0 in the prior quarter.
• Over the last five years, Non-Current Debt for EPRX reached as high as $62709.0 in Q4 2022 and fell as low as $21209.0 in Q2 2024.
• Historically, Non-Current Debt has averaged $47184.8 across 3 years, with a median of $52410.5 in 2022.
• On a YoY basis, Non-Current Debt climbed as much as 0.0% in 2023 and fell as far as 0.0% in 2023.
• Year by year, Non-Current Debt stood at $62709.0 in 2022, then changed by 0.0% to $62709.0 in 2023, then slumped by 66.18% to $21209.0 in 2024.
• Per Business Quant data, the three most recent Non-Current Debt figures were $21209.0 in Q2 2024, $42112.0 in Q1 2024, and $62709.0 in Q4 2023.